Macular disease

May is Macula Month. To mark 2023’s awareness campaign Macular Disease Foundation Australia reveals new insights into the health and...

US biopharmaceutical company Iveric Bio has released new data for its avacincaptad pegol (ACP) therapy for geographic atrophy (GA), which...

In a historic first, the US Food and Drug Administration (FDA) has approved SYFOVRE (pegcetacoplan injection), manufactured by global biopharmaceutical...

The treatment landscape for wet and dry AMD is undergoing a seismic shift in Australia. CERA’s head of macular research...

Roche Australia has announced the Australian Therapeutic Goods Administration (TGA) has registered Vabysmo (faricimab) for the treatment of neovascular or...

The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens...

The US Food and Drug Administration (FDA) has approved the Susvimo implant which delivers ranibizumab continuously, offering patients living with...

Prominent Melbourne retinal disease researcher Professor Robyn Guymer is encouraged by the Phase 3 results of a trial she’s been...

A clinical trial at Sydney Eye Hospital is evaluating the safety and efficacy of using infrared light to treat macular...

Eight Australian researchers are taking their projects to the next level with a share of more than $1 million in...